All the news

  • Experimental therapy improves liver health in people with fatty liver disease

    Liz Highleyman / 31 January 2019

    NGM282, an experimental fibroblast growth factor analogue, reduced liver fat build-up and the development of scar tissue in people with non-alcoholic steatohepatitis, according to studies presented at the recent AASLD Liver Meeting in ...

  • Aramchol reduces liver fat in people with NASH

    Liz Highleyman / 02 January 2019

    A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ...

  • Lean people can develop fatty liver disease

    Liz Highleyman / 17 December 2018

    Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ...

  • Burden of severe liver disease due to fatty liver will more than double by 2030

    Keith Alcorn / 07 December 2018

    If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease (NAFLD) in western Europe, China, Japan and the United States by ...

  • Thyroid hormone receptor agonists reduce liver fat in people with NAFLD

    Liz Highleyman / 29 November 2018

    Thyroid hormone activation appears to be a promising approach for treating fatty liver disease, according to a pair of studies presented at the AASLD Liver Meeting this month in San Francisco. Two thyroid ...

  • People with fatty liver disease are at greater risk for multiple cancers

    Liz Highleyman / 12 November 2018

    People with non-alcoholic fatty liver disease (NAFLD) were found to have higher rates of cancer, with the greatest increase observed for gastrointestinal cancers, according to findings presented yesterday at the 2018 AASLD Liver ...

  • HIV infection is a risk factor for liver fat accumulation

    Liz Highleyman / 13 August 2018

    People living with HIV are about twice as likely to develop steatosis, or fat accumulation in the liver, even if they don't have hepatitis B or C co-infection, according to a study presented at ...

  • Mixed results for experimental therapies for NASH

    Liz Highleyman / 22 June 2018

    The recent International Liver Congress in Paris featured several presentations on investigational therapies for fatty liver disease. Drugs with a range of different mechanisms – including the thyroid hormone receptor agonist MGL-3196, ...

  • Cenicriviroc treatment improves liver fibrosis in people with NASH

    Liz Highleyman / 13 April 2018

    Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatohepatitis (NASH) after two years of follow-up, according to a ...

  • New EACS treatment guidelines

    Keith Alcorn / 31 October 2017

    Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as people with hepatitis C monoinfection, ...

← First12Next →